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Editorial
Cervical cancer is the third leading cause of female cancer
worldwide and is the second most common cause of cancer
related deaths in women in undeveloped countries.1 The
incident rate varies with the prevalence of risk factors and
the lack of adequate screening programs, reaching 80 cases
per 100,000 inhabitants in Recife, Brazil.2 Despite advances
in treatment, cervical cancer still maintains high rates of
morbidity and mortality – the recurrence rate and associated
death is approximately 30%. Data from the UK show that
one third of patients will die within 5 years of diagnosis. 3
For all these reasons cervical cancer can be considered a
public health issue especially in developing countries.
The International Federation of Gynecology and Obstetrics
(FIGO) stage system is the most widely used for cervical
cancer. This system emphasizes the clinical parameters at the
expense of morphological and functional examinations,
which facilitates its applicability in developing countries -
where additional tests are expensive and not available. The
main limitations are the fact that this system is examiner
dependent, difficult to reproduce, and difficult to perform in
obese patients or those with unfavorable anatomy.
Although without altering the classification proposed by
FIGO, exams are valuable in this disease as they tend to
guide the practitioner toward more accurate treatment. Fur-
thermore, they are important to assess the response to treat-
ment, which is of paramount importance since additional
therapies (i.e. hysterectomy) may be used in cases of persis-
tent disease.
The 18-FDG PET stands out as the most used and studied
functional test in cervical cancer. Unfortunately, PET is not
available to many treatment centers around the world, espe-
cially in those that have the highest incidence rates – as the
funds needed to obtain its tracer make it cost prohibitive.
In this context, a much more cost effective relation is the
MRI. Stenstedt et al. 4 studied the impact of MRI in staging
and follow-up of cervical lesions and concluded that the
addition of this examination alter the staging proposed by
FIGO and changes the treatment plan in many cases. In
2013, Kraljevic et al. 5 performed a study comparing the
FIGO staging and MRI preoperatively and correlated these
findings with the pathological outcome in patients treated
surgically. They concluded that MRI is better than clinical
staging (accuracy of 90.9% versus 79.0%).5
Novel advances such as diffusion weighted image (DWI)
(sequence that is sensitive to the random motion of water
molecules - i.e., Brownian motion) allow us to evaluate
changes during therapy. Restriction to this diffusion move-
ment is directly associated to the degree of cellularity of the
tissue and thus is related to primary malignancy and metas-
tasis.6 An actual issue is whether its changes are predictive of
response: the DWI derived apparent diffusion coefficient
(ADC) is capable to quantify the magnitude of this water
diffusion and has been used extensively as a biomarker for
therapeutic response in many cancer types.
Emerging studies seek to consolidate the actual role of MRI
and their different weights in the staging and therapeutic
monitoring of cervical cancer. Advantages such as
cost-effectiveness (pathology is predominant in developing
countries) and absence of need of contrast (essential in cases
where there is impairment of renal function) add to this
exam key features to this pathology. It is not difficult to pre-
dict that if new studies demonstrate in practice these ad-
vantages, MRI/DWI could be considered essential in the
future.
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